Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...

NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01 ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

New 16- and 18-inch Predator Helios Neo AI devices are powered by new Intel Core Ultra 200HX Series processors and NVIDIA GeForce RTX 50 Series Laptop GPUs KATOWICE, Poland, Feb. 7, 2025 ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the ...

NeoGenomics Inc (NEO) reports robust revenue growth and improved margins, while navigating challenges in the pharma segment and ongoing litigation.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.The company traded as ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...

NASDAQ:NEO opened at $14.42 on Monday. NeoGenomics has a 1 year low of $12.13 and a 1 year high of $19.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio ...